Acute Liver Injury / Acute Hepatitis
Acute hepatocellular injury with elevated transaminases ± jaundice — viral, DILI, or ischemic etiology drives management
Symptoms / Associated Sx
Fatigue, malaise, anorexia, nausea, vomiting, RUQ discomfort
Jaundice, dark urine, pale stools
Fever, myalgias, arthralgias (viral); rash, eosinophilia (DILI hypersensitivity)
Confusion, coagulopathy (acute liver failure — severe end)
Denies
Alcohol use (shifts away from alcoholic hepatitis)
Recent travel, shellfish, sick contacts (rules out HAV if absent)
New medications/supplements within 3 months (rules out DILI if absent)
Hypotension, cardiac event (rules out ischemic hepatitis if hemodynamically stable)
Social History (SHx)
IV drug use, high-risk sexual behavior (HBV/HCV/HDV), travel to endemic areas (HAV/HEV), recent medications or supplements, acetaminophen use, alcohol, recent hypotensive episode (ischemic hepatitis).
Main Etiology
Viral: HAV (fecal-oral, self-limited), HBV (acute or reactivation), HCV (rarely acute), HEV (travelers/pregnant), CMV, EBV
DILI: APAP (most common ALF in U.S.), isoniazid, statins, amoxicillin-clavulanate, NSAIDs, nitrofurantoin, herbals
Ischemic hepatitis: Shock liver — right heart failure, cardiogenic shock, hypotension; transaminases >1000–100,000 U/L
AIH: Young women; elevated IgG; ANA/ASMA; responds to steroids
Wilson's disease: Young patient; Kayser-Fleischer rings; hemolytic anemia; low ALP
Most Common DDx
Alcoholic hepatitis (AST:ALT >2:1; heavy alcohol use history; GGT markedly elevated; no ischemic precipitant)
Ischemic hepatitis / shock liver (transaminases dramatically elevated >1000–10,000; preceding hypotension or cardiac event; rapid normalization with resuscitation; echo often abnormal)
Acute cholecystitis / cholangitis (RUQ pain + fever; CBD dilation; elevated ALP/bilirubin > transaminases; imaging confirms biliary pathology)
Autoimmune hepatitis (young-middle aged women; ANA + ASMA + elevated IgG; liver biopsy confirms; responds to steroids)
Wilson's disease in young patient (low ALP — key clue; Coombs-negative hemolytic anemia; Kayser-Fleischer rings; ceruloplasmin low)
HELLP syndrome (pregnant/postpartum — thrombocytopenia + hemolysis + elevated LFTs; unique to pregnancy)
Budd-Chiari (hepatic vein thrombosis; painful hepatomegaly; ascites; Doppler shows no hepatic venous flow)
DATA
LFTs (AST/ALT/ALP/GGT/bilirubin direct vs. indirect), PT/INR, albumin, CBC, BMP
Viral serology: HAV IgM, HBsAg, HBcAb IgM, HCV Ab + RNA, HEV IgM, EBV/CMV PCR
ANA, ASMA, IgG (AIH); ceruloplasmin, serum copper (Wilson's); APAP level
Abdominal US with Doppler; echo if ischemic hepatitis suspected; liver biopsy if etiology unclear
Home Meds
All hepatotoxic medications — identify and hold offending agent
APAP (critical — assess total dose and timing); statins (hold until LFTs improve); herbal supplements (hold all)
Plan
Identify and remove causative agent; supportive care; avoid nephrotoxins; serial LFTs q24–48h
APAP overdose: NAC 150 mg/kg IV over 1h → 50 mg/kg over 4h → 100 mg/kg over 16h; Rumack-Matthew nomogram; poison control; transplant evaluation if ALF
Viral: HAV → supportive; acute HBV → tenofovir or entecavir if severe (INR >1.5 or jaundice); HBV reactivation → start antiviral urgently; HCV → defer 12 weeks (many clear spontaneously)
Ischemic hepatitis: Treat underlying cause; hemodynamic resuscitation; transaminases fall rapidly with perfusion restoration
AIH: Prednisone 40–60 mg daily ± azathioprine 50–100 mg daily; GI/hepatology + liver biopsy
ALF (INR >1.5 + HE within 26 weeks): ICU; NAC infusion; emergent transplant evaluation
Daily CBC, CMP, PT/INR, glucose; hepatology consult; toxicology if APAP/DILI; PT/OT when stabilized
Discharge: Avoid hepatotoxins (APAP <2 g/day; no alcohol; no herbals); LFTs recheck 2–4 weeks; hepatology follow-up for viral/AIH treatment; HAV/HBV vaccination if non-immune
Red Flags
INR >1.5 + any HE → acute liver failure → ICU + emergent transplant evaluation
Transaminases >10,000 → ischemic hepatitis or APAP toxicity → hemodynamic assessment immediately
APAP + INR rising despite NAC → ALF trajectory → transplant team now
HBV reactivation (immunosuppressed) → fulminant hepatitis → start antiviral immediately
Hy's Law in DILI (transaminases >3× ULN + bilirubin >2× ULN) → ~10% mortality → stop all drugs
Senior IM Resident Pearls
Ischemic hepatitis produces the most dramatically elevated transaminases (>10,000 common) — always ask about preceding hypotension or cardiac event
Rumack-Matthew nomogram: APAP level vs. time post-ingestion; treatment line at 150 mcg/mL at 4h
Hy's Law for DILI: Transaminases >3× ULN + bilirubin >2× ULN + no other cause = ~10% fatal outcome
HBV reactivation critical in patients on rituximab, steroids, anti-TNF — screen all with HBsAg + HBcAb before immunosuppression
Wilson's disease pearl: Low ALP + hemolysis + hepatitis in young = Wilson's until proven otherwise
Common mistake: Permanently stopping statins after mild transaminase elevation — rechallenge is reasonable after normalization; severe hepatotoxicity is rare
orders
Labs
Admission Labs
CBC with diff
CMP
BMP
PT/INR
PTT
Albumin
Glucose
Magnesium
Phosphorus
Viral Hepatitis Workup
HAV IgM
HBsAg
HBcAb IgM
HBsAb
HCV Ab
HCV RNA
HEV IgM (if indicated)
CMV PCR
EBV PCR
DILI / Toxicology Workup
Acetaminophen level
Salicylate level (if concern)
Urine drug screen
Ethanol level
Autoimmune Hepatitis Workup
ANA
ASMA
IgG level
Anti-LKM antibodies (if indicated)
Wilson Disease Workup
Ceruloplasmin
Serum copper
24-hour urine copper
Additional Labs
LDH (often very high in ischemic hepatitis)
Lactate
AFP
Pregnancy test if applicable
Trending Labs
CBC daily
CMP daily
PT/INR daily
Glucose q6–8 hr if severe disease
AST/ALT daily
Bilirubin daily
Imaging
Initial Imaging
RUQ Ultrasound with Doppler
Biliary obstruction
Portal vein thrombosis
Budd-Chiari
Liver morphology
Additional Imaging
CT Abdomen/Pelvis
If:
Malignancy concern
Unclear diagnosis
Vascular pathology
Echocardiogram
If:
Ischemic hepatitis
CHF
Cardiogenic shock
Specialty Imaging
MRCP
If:
Biliary obstruction suspected
Cholangitis concern
Procedures
Usually Not Needed Initially
Liver Biopsy
If:
Etiology unclear
Autoimmune hepatitis suspected
Persistent unexplained hepatitis
ICU Procedures
If ALF:
Central line
Arterial line
Frequent neuro checks
Medications
General Supportive Care
IV Fluids
LR or NS as indicated
Avoid volume overload
Avoid
Hepatotoxic medications
NSAIDs
Alcohol
Herbal supplements
Acetaminophen Toxicity
N-Acetylcysteine (NAC)
Loading
150 mg/kg IV over 1 hr
Second Infusion
50 mg/kg IV over 4 hr
Third Infusion
100 mg/kg IV over 16 hr
Additional
Poison Control consult
Toxicology consult
Acute HBV
Severe Disease
(INR >1.5, severe jaundice, ALF)
Tenofovir
300 mg PO daily
OR
Entecavir
0.5 mg PO daily
HBV Reactivation
Immediate Treatment
Tenofovir 300 mg PO daily
OR
Entecavir 0.5 mg PO daily
Autoimmune Hepatitis
Prednisone
40–60 mg PO daily
Steroid-Sparing
Azathioprine 50–100 mg PO daily
(Hepatology guided)
Ischemic Hepatitis
Treatment
Treat shock
Restore perfusion
Treat CHF
Treat sepsis
Optimize oxygen delivery
No specific liver-directed therapy.
Acute Liver Failure
Continue NAC
Even if non-APAP ALF
ICU Monitoring
Neuro checks
Glucose monitoring
Airway assessment
Early Transplant Evaluation
Hold Medications
Hold All Potential Hepatotoxins
Acetaminophen
Statins
Herbals/supplements
Amoxicillin-clavulanate
Nitrofurantoin
Isoniazid
Valproate
Methotrexate
Review Carefully
Anticoagulants
Sedatives
Consults
Hepatology (Most Patients)
Severe hepatitis
ALF
AIH
Viral hepatitis
Toxicology
Acetaminophen overdose
DILI
Poison Control
Any overdose concern
Transplant Team
If:
ALF
INR >1.5 + HE
Rapid deterioration
Critical Care
Acute liver failure
Shock
Encephalopathy
PT/OT
Deconditioning
Nursing Orders
Monitoring
Neuro checks q4 hr
Strict I&O
Daily weights
Fall precautions
Diet
Regular diet if tolerated
Avoid alcohol completely
Notify Physician
New confusion
Worsening jaundice
Hypoglycemia
Bleeding
INR rise
Worsening LFTs
Follow-Up Studies
Follow
Viral serologies
Autoimmune panel
Ceruloplasmin
Copper studies
APAP level
Ultrasound findings
Daily
AST
ALT
Bilirubin
INR
Creatinine